Basilea Pharmaceutica AG (BPMUF) Stock Analysis

Basilea Pharmaceutica AG (BPMUF) Healthcare & Pipeline Overview

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company specializing in oncology and anti-infectives, offering treatments like Cresemba and Zevtera. With a 17.9% profit margin and a beta of 0.46, the company focuses on addressing unmet medical needs through ongoing clinical trials and strategic product development within the biotechnology sector.

What Is the Investment Thesis for BPMUF?

With a market capitalization of $958M and a P/E ratio of 15.09, the company demonstrates financial stability and growth potential. Key value drivers include the continued commercial success of Cresemba and Zevtera, as well as the advancement of Derazantinib and Lisavanbulin through clinical trials. The company's 74.3% gross margin indicates strong pricing power and efficient operations. Upcoming clinical trial results and potential regulatory approvals for its pipeline candidates serve as significant growth catalysts. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.

Based on FMP financials and quantitative analysis

BPMUF Key Highlights

Market Cap of $958M reflects investor confidence in Basilea's pipeline and commercial products.

• P/E ratio of 15.09 indicates a reasonable valuation compared to its earnings.
• Profit Margin of 17.9% demonstrates efficient operations and profitability.
• Gross Margin of 74.3% showcases strong pricing power and cost management.
• Beta of 0.46 suggests lower volatility compared to the overall market, making it a potentially stable investment.

Who Are BPMUF's Competitors?

BPMUF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BPMUF's Key Strengths?

Specialized expertise in oncology and anti-infectives.

• Commercialized products with established revenue streams.
• Promising pipeline of drug candidates in clinical trials.
• Strong gross margin.

What Are BPMUF's Weaknesses?

Reliance on a limited number of products.

• High R&D expenses.
• Dependence on regulatory approvals.
• Competition from larger pharmaceutical companies.

What Could Drive BPMUF Stock Higher?

Phase III clinical trial results for Cresemba in Japan for invasive fungal infections.

• Phase III clinical trial results for Zevtera in acute bacterial skin and skin structure infections and Staphylococcus aureus bacteremia.
• Phase 2 clinical trial progress for Derazantinib in bile duct cancer.
• Phase ½ clinical trial progress for Derazantinib in bladder and stomach cancer.
• Development progress of Lisavanbulin as a tumor checkpoint controller drug.

What Are the Key Risks for BPMUF?

Clinical trial failures for drug candidates.

• Regulatory delays or rejections.
• Competition from established pharmaceutical companies.
• Patent expirations and generic drug entry.
• Product liability claims.

What Are the Growth Opportunities for BPMUF?

• Expansion of Cresemba's Market Reach: Cresemba, Basilea's antifungal drug, has the potential for significant growth through geographic expansion and label extensions. The global market for antifungal drugs is projected to reach $17.5 billion by 2028. Securing regulatory approvals in additional markets, such as Japan, and expanding its use to treat other fungal infections could drive substantial revenue growth for Basilea.
• Advancement of Derazantinib in Oncology: Derazantinib, a small molecule inhibitor, is currently in Phase 2 clinical trials for bile duct cancer and Phase ½ clinical trial for bladder and stomach cancer. The oncology market is one of the largest and fastest-growing segments in the pharmaceutical industry. Positive clinical trial results and subsequent regulatory approval could position Derazantinib as a valuable asset in Basilea's oncology portfolio, addressing a significant unmet medical need.
• Development of Lisavanbulin as a Tumor Checkpoint Controller: Lisavanbulin, a tumor checkpoint controller drug, represents a novel approach to cancer treatment. The market for immunotherapies and checkpoint inhibitors is experiencing rapid growth. Successful development and commercialization of Lisavanbulin could provide Basilea with a competitive advantage in the oncology space, capturing a significant share of the immunotherapy market.
• Lifecycle Management of Zevtera: Zevtera, Basilea's antibiotic, is currently in Phase III clinical trials for acute bacterial skin and skin structure infections and Staphylococcus aureus bacteremia. Expanding the indications for Zevtera through successful clinical trials and regulatory approvals can extend its market exclusivity and drive revenue growth. The increasing prevalence of antibiotic-resistant bacteria underscores the need for new and effective antibiotics, creating a favorable market environment for Zevtera.
• Strategic Partnerships and Acquisitions: Basilea can pursue strategic partnerships and acquisitions to expand its pipeline and market reach. Collaborating with other biotechnology and pharmaceutical companies can provide access to new technologies, drug candidates, and markets. Acquiring complementary assets can strengthen Basilea's competitive position and accelerate its growth trajectory. These strategic initiatives can enhance Basilea's long-term value and create synergies across its operations.

What Are BPMUF's Competitive Advantages?

• Patented pharmaceutical products.
• Specialized expertise in oncology and anti-infectives.
• Established distribution network.
• Strong brand reputation.

What Does BPMUF Do?

Founded in 2000 and headquartered in Basel, Switzerland, Basilea Pharmaceutica AG is a biopharmaceutical company dedicated to developing and commercializing innovative products that address critical medical needs in oncology and anti-infectives. The company's portfolio includes Cresemba, an intravenous and oral azole antifungal drug used to treat invasive aspergillosis and mucormycosis. Cresemba is available in the United States and the European Union, and is currently in Phase III clinical trials in Japan for invasive fungal infections. Another key product is Zevtera, an antibiotic used for treating community and hospital-acquired pneumonia. Zevtera is also undergoing Phase III clinical trials for acute bacterial skin and skin structure infections, as well as Staphylococcus aureus bacteremia. Basilea is also developing Derazantinib, a small molecule inhibitor in Phase 2 clinical trial for bile duct cancer and Phase ½ clinical trial for bladder and stomach cancer. Additionally, they are developing Lisavanbulin, a tumor checkpoint controller drug. Basilea's strategic focus on these therapeutic areas positions it to capitalize on the growing demand for novel treatments in oncology and infectious diseases.

What Products and Services Does BPMUF Offer?

• Develop and commercialize pharmaceutical products.
• Focus on oncology and anti-infectives therapeutic areas.
• Offer Cresemba for the treatment of invasive aspergillosis and mucormycosis.
• Provide Zevtera for the treatment of community and hospital-acquired pneumonia.
• Engage in clinical trials for new drug candidates.
• Develop Derazantinib for bile duct, bladder, and stomach cancer.
• Develop Lisavanbulin as a tumor checkpoint controller drug.

How Does BPMUF Make Money?

• Develop and license pharmaceutical products.
• Generate revenue through product sales.
• Invest in research and development to expand product pipeline.
• Partner with other companies for commercialization and distribution.

What Industry Does BPMUF Operate In?

Basilea Pharmaceutica AG operates within the biotechnology industry, which is characterized by rapid innovation and high regulatory scrutiny. The market for anti-infectives and oncology drugs is substantial and growing, driven by an aging population and increasing prevalence of chronic diseases. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share. Basilea differentiates itself through its focus on specific therapeutic areas and its pipeline of novel drug candidates. The biotechnology industry is expected to continue its growth trajectory, fueled by advancements in genomics, personalized medicine, and drug delivery technologies.

Who Are BPMUF's Key Customers?

• Hospitals and healthcare providers.
• Patients with fungal infections and pneumonia.
• Oncology patients.
• Pharmaceutical distributors.

Company Profile

Basilea Pharmaceutica AG operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Allschwil, CH. The company is led by CEO David Veitch. BPMUF has traded publicly since 2015.

Basilea Pharmaceutica AG Financial Trajectory

Basilea Pharmaceutica AG (BPMUF) reported $145.0M in revenue for Jun 2026, a decline of 7.9% compared to the prior quarter. The company recorded net income of $34.1M, with diluted EPS of $2.47. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, BPMUF averaged $2.84 in diluted EPS.

How Basilea Pharmaceutica AG Is Valued

Basilea Pharmaceutica AG carries a market capitalization of $958M, placing it in the small-cap category.

Return on equity for Basilea Pharmaceutica AG stands at 28.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 11.5%, showing how much profit it generates from its asset base. BPMUF trades at a trailing price-to-earnings ratio of 15.09, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 7.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.11 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.1%, the inverse of the P/E and a quick read on earnings relative to price.

Basilea Pharmaceutica AG's Piotroski F-Score is 9/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.56 places it in the safe zone, indicating low near-term bankruptcy risk.

Basilea Pharmaceutica AG has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 53.2% above estimates on average.

Wall Street analysts project Basilea Pharmaceutica AG revenue of about $255.8M for fiscal 2026, with EPS near $4.31.

BPMUF Financials

BPMUF Latest News

BPMUF Analyst Consensus

BPMUF MoonshotScore

BPMUF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources